Growth Metrics

bioAffinity Technologies (BIAF) Share-based Compensation (2021 - 2026)

bioAffinity Technologies has reported Share-based Compensation over the past 5 years, most recently at $14340.0 for Q1 2026.

  • Quarterly Share-based Compensation fell 95.61% to $14340.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $359198.0 through Mar 2026, down 65.25% year-over-year, with the annual reading at $671474.0 for FY2025, 32.15% down from the prior year.
  • Share-based Compensation was $14340.0 for Q1 2026 at bioAffinity Technologies, down from $66119.0 in the prior quarter.
  • Over five years, Share-based Compensation peaked at $326616.0 in Q1 2025 and troughed at $14340.0 in Q1 2026.
  • The 5-year median for Share-based Compensation is $157613.0 (2023), against an average of $151277.0.
  • Year-over-year, Share-based Compensation surged 538.01% in 2023 and then crashed 95.61% in 2026.
  • A 5-year view of Share-based Compensation shows it stood at $36847.0 in 2022, then surged by 536.44% to $234510.0 in 2023, then decreased by 0.18% to $234087.0 in 2024, then plummeted by 71.75% to $66119.0 in 2025, then plummeted by 78.31% to $14340.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Share-based Compensation are $14340.0 (Q1 2026), $66119.0 (Q4 2025), and $67132.0 (Q3 2025).